Loading patent…
AssigneeAgilent Technologies, Inc.
InventorsDebra Hanks, Mai Nguyen, Marko Srdanov, Che Hutson
Estimating the term…
Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent. In certain embodiments, the method includes determining, by immunohistochemistry, the number of PD-L1 positive malignant cells in a tumor tissue section as well as the number of infiltrating non-malignant cells and/or non-malignant cells of the stromal interface area. The infiltrating non-malignant cells and/or non-malignant cells of the stromal interface area are positive for a marker selected from PD-L1, CD8, CD68, and any combination thereof. Compositions and kits or performing the disclosed methods are also provided.
A method for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent, the method comprising:
A kit for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent, comprising:
Dependencies are inferred from the claim text.